Gaceta Mexicana de Oncologia最新文献

{"title":"Serie de casos de pacientes con hepatocarcinoma tratados con sorafenib como terapia puente a quimioembolización y finalmente como paliativo","authors":"Nora Hilda Chávez Hernández ,&nbsp;Alejandro Antonio Sánchez Cruz","doi":"10.1016/j.gamo.2016.07.006","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.006","url":null,"abstract":"<div><h3>Introduction</h3><p>There are patients with hepatocellular carcinoma who are candidates for chemoembolisation that face long delays due to waiting for the imaging assessment of that procedure by the radiologist.</p></div><div><h3>Objective</h3><p>To describe the results of a series of patients who received sorafenib as a bridge therapy during the time of deferral for chemoembolisation.</p></div><div><h3>Material and methods</h3><p>An analysis was made of the records of patients with hepatocellular carcinoma that were assessed in the digestive tract neoplasms functional unit (UFNAD) from August 2015 to February 2016, in order to detect those that had been treated with sorafenib as a bridge to chemoembolisation.</p></div><div><h3>Results</h3><p>A total of 14 patients with hepatocellular carcinoma were evaluated in the UFNAD in this period, with 9 of them receiving sorafenib as bridge therapy. It was used as initial therapy in 7, after radiofrequency in 2. None of them received the local therapy for which the sorafenib was planned as bridge, and all for reasons other than progression.</p></div><div><h3>Conclusion</h3><p>If chemoembolisation has to delayed, it is feasible to use sorafenib as a bridging therapy, which can also serve to avoid delay in palliative therapy if the patient turns out not to be a candidate for local therapy.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 195-198"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desempeño cognitivo en pacientes con cáncer de mama tratadas con quimioterapia","authors":"Jasmín Bonilla Santos ,&nbsp;Ruth Rodríguez Orjuela ,&nbsp;Paula Andrea Trujillo Sánchez ,&nbsp;Andrea del Pilar González Rojas ,&nbsp;Alfredis Gonzalez Hernandez","doi":"10.1016/j.gamo.2016.07.004","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.004","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the cognitive processes in patients with breast cancer during and after chemotherapy.</p></div><div><h3>Method</h3><p>A comparative study was conducted in which an assessment was made of processing speed, attention, memory, and executive functions in 14 women after receiving chemotherapy treatment and in 14 healthy women.</p></div><div><h3>Results</h3><p>The results show significant differences in the memory process, specifically in the evocation and working memory. No significant differences were found in the depression and anxiety scales.</p></div><div><h3>Conclusions</h3><p>Patients with breast cancer and received treatment with chemotherapy had a lower performance in the verbal memory process compared to the control group, as well as a significant number of intrusions, which suggests involvement in this process.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 199-206"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutropenia febril: el punto de vista del hematólogo","authors":"José Ramón Rivas Llamas","doi":"10.1016/j.gamo.2016.07.005","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.005","url":null,"abstract":"<div><p>Notable advances have been made in the last 20 years as regards treatment of the haematology-oncology patient. Without a doubt, one of the most remarkable advances has been the reduction in infectious complications, as well as the decrease in the neutropenic period due to the use of haematopoietic growing factors. Nevertheless, febrile neutropenia (FN) is a severe consequence of using myelosuppressive chemotherapy, which usually leads to hospital admission, and the use of intravenous antibiotics, using important health system resources. FN is related to dose reductions and delay or suspension of chemotherapy, affecting the final outcome of treatment. It is essential to be able to identify patients with a high risk of developing FN so that they can receive optimal chemotherapy, FN risk management, as well as receiving a timely diagnosis and treatment.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 212-221"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Los efectos carcinogénicos del acetaldehído. Una visión actual","authors":"Xaira Jimena Rivera Gutiérrez,&nbsp;Orestes de Jesús Cobos Quevedo,&nbsp;José María Remes Troche","doi":"10.1016/j.gamo.2016.07.007","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.007","url":null,"abstract":"<div><p>Acetaldehyde, associated with chronic consumption of alcoholic beverages and smoking, has recently been classified as a Group 1 carcinogen to humans. Microbes are responsible for the bulk of acetaldehyde production from ethanol both in saliva and gastric juice in Helicobacter pylori-infected and achlorhydria patients. Acetaldehyde is the most abundant carcinogen in tobacco smoke, and it readily dissolves in the saliva during smoking. Many foodstuffs and ‘non-alcoholic’ beverages are significant but unrecognised sources of local acetaldehyde exposure. The cumulative cancer risk associated with increasing acetaldehyde exposure suggests the need for worldwide screening of the acetaldehyde levels of alcoholic beverages, as well of the ethanol and acetaldehyde of food produced by fermentation. Risk groups with alcohol dehydrogenase (ADH)-and aldehyde dehydrogenase 2 (ALDH2) gene polymorphisms, H. pylori infection or achlorhydria atrophic gastritis, or both, should be screened and educated in this health issue. L-cysteine formulations binding carcinogenic acetaldehyde locally in the stomach provide new means for intervention studies.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 231-239"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ética en oncología","authors":"Maricruz Pérez Amador del Cueto ,&nbsp;Francisco Javier Ochoa Carrillo","doi":"10.1016/j.gamo.2016.09.001","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.001","url":null,"abstract":"","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 193-194"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137284696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fe de errores de «Prevalencia de artralgias y mialgias en pacientes con cáncer de mama en tratamiento con inhibidores de la aromatasa»","authors":"Eduardo Téllez Bernal ,&nbsp;Oscar Falcón Flores ,&nbsp;Rosa María Méndez Tamariz ,&nbsp;Rita Zalapa Velázquez ,&nbsp;José Manuel Aguilar Priego ,&nbsp;Alma Mendoza López","doi":"10.1016/j.gamo.2016.08.001","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.08.001","url":null,"abstract":"","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Page 260"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137302311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma endoluminal","authors":"David Pedrazas López ,&nbsp;Bernat de Pablo Márquez ,&nbsp;David García Font ,&nbsp;Josep Alins Presas ,&nbsp;Jordi Esplugas Abòs","doi":"10.1016/j.gamo.2016.07.008","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.008","url":null,"abstract":"<div><p>The case is reported on a 72 year-old woman with dyspnoea and chest pain. Diagnostic tests showed lung images with a high suspicion of malignancy and an endoluminal defect in the pulmonary artery. Anticoagulant treatment was initiated under the diagnosis of pulmonary embolism and probable lung cancer. Due to a lack of response to the treatment, an MRI and PET-CT were performed, providing the diagnosis of a fusocellular sarcoma with pulmonary metastasis.</p><p>Endoluminal sarcoma is an uncommon condition and is frequently misdiagnosed due to the clinical and radiological similarity with pulmonary embolism. This condition must be suspected when faced with some radiological characteristics and the lack of response to anticoagulant treatment.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 254-257"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Costo-efectividad de panitumumab","authors":"Eleanor Saunders","doi":"10.1016/j.gamo.2016.06.002","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.06.002","url":null,"abstract":"","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 258-259"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supresión tumoral por microARN en el cáncer gástrico","authors":"Luis Alejandro Arias Sosa ,&nbsp;Bibiana Matilde Bernal Gómez ,&nbsp;Andrés Felipe Cuspoca Orduz","doi":"10.1016/j.gamo.2016.07.003","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.003","url":null,"abstract":"<div><p>Gastric cancer is a disease that causes high mortality worldwide, and in some developing countries like Colombia it is the first in terms of cause of cancer deaths. Among the most crucial topics in the disease is the study of tumour suppressors, which due to their biological functions inhibit the so-called hallmarks of cancer. There has been a major breakthrough in this field with multiple molecules and their respective mechanisms of action being described. The study of miRNAs, which inhibit the expression of specific genes and preventing its translation, has expanded greatly in recent years. Several studies have established that these miRNAs may act as tumour suppressors gastric cancers by downregulating genes that promote tumorigenesis, and by controlling the development of the hallmarks of cancer. MiRNAs are also interesting since a single one can control multiple signalling pathways related to the onset and progression of gastric malignancies, thus making them a promising tool for diagnosis, prognosis, monitoring, and treatment of the disease.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 222-230"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiencia del Instituto Regional de Tratamiento del Cáncer en el manejo del cáncer cervicouterino con radioterapia","authors":"Ciria Vázquez Macías ,&nbsp;Mónica Miroslava García Silva ,&nbsp;Emilio Torres Medina ,&nbsp;José Francisco Figueroa Sandoval","doi":"10.1016/j.gamo.2016.07.009","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.07.009","url":null,"abstract":"<div><h3>Background</h3><p>Cervical uterine cancer (CUC) is an important public health problem in our country. The treatment of this cancer depends on the clinical stage. The therapeutic modalities used may be surgery, radiotherapy, and a combination of radiotherapy plus chemotherapy.</p></div><div><h3>Objective</h3><p>To describe the experience of the Regional Institute of Cancer Treatment (RICT) in patients with cervical cancer treated with external radiotherapy plus brachytherapy with iridium 192.</p></div><div><h3>Method</h3><p>A descriptive, retrospective study was conducted on 32 patients with cervical uterine cancer treated by external radiotherapy with linear accelerator, a 5000 dose of cGy (isocentric technique) plus 2100 cGy with high dose rate (HDR) brachytherapy in 3 sessions. Patients with clinical stage IA2 were treated only with brachytherapy, with a minimum follow-up of 2 years.</p></div><div><h3>Results</h3><p>There were 2 patients in stage IA2, 7 in stage IB1-IB2, 1 patient in IIA, 11 patients in IIB, 8 in stage IIIB, 1 patient in stage IVA 1, and 2 patients unclassified. Only 3 patients (2 in stage IIB, and 1 in stage IIIB) were treated with concomitant chemotherapy. Immediate morbidity was grade II cystitis in 3 patients and grade III proctitis in 3 patients. The delayed morbidity included grade II proctitis in 3 patients, grade I cystitis in 3 patients, partial synechiae in 5 patients, and complete synechiae in 4 patients. Twenty-three patients survived with no tumour activity, which included, brachytherapy only in 2 in stage IA, 7 in IB1-IB2, 1 in IIA, 7 in stage IIB, 4 in stage IIIB, 1 in stage IVA, and 1 in unclassified. Of the 9 patients that died, 4 were in stage IIB, 4 in stage IIIB, and 1 unclassified.</p></div><div><h3>Conclusion</h3><p>Locoregional control and survival are similar to those reported in the literature, but with less morbidity.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 4","pages":"Pages 207-211"},"PeriodicalIF":0.1,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.07.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137429291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}